1. Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review

   • Ou Sha
   • Junfei Niu
   • Wenqi Jiang

   Review Article Open access 03 February 2013 Pages: 1387 - 1393

   

2. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

   • Carolyn D. Britten

   Review Article 27 February 2013 Pages: 1395 - 1409

   

3. Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin

   • Yutaka Ueda
   • Takayuki Enomoto
   • Tadashi Kimura

   Original Article 21 March 2013 Pages: 1411 - 1416

   

4. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma

   • Stephen L. Chan
   • Chi-Hang Wong
   • Winnie Yeo

   Original Article 02 April 2013 Pages: 1417 - 1425

   

5. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan

   • Kenjiro Aogi
   • Yoshiaki Rai
   • Shigemitsu Takashima

   Original Article 28 March 2013 Pages: 1427 - 1433

   

6. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer

   • Jin Won Kim
   • Hyun Jin Cho
   • Yung-Jue Bang

   Original Article 30 April 2013 Pages: 1435 - 1443

   

7. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901

   • Young Hak Kim
   • Masataka Hirabayashi
   • Michiaki Mishima

   Original Article 27 March 2013 Pages: 1445 - 1451

   

8. The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats

   • Feng You
   • Jinping Hu
   • Yan Li

   Original Article 05 April 2013 Pages: 1453 - 1462

   

9. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer

   • Lucía Cortejoso
   • María I. García
   • Luis A. López-Fernández

   Original Article 31 March 2013 Pages: 1463 - 1472

10. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors

    • J. F. Deeken
    • B. Shimkus
    • S. Zhang

    Original Article 16 April 2013 Pages: 1473 - 1483

    

11. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer

    • Davendra P. S. Sohal
    • James M. Metz
    • Peter J. O’Dwyer

    Original Article 27 March 2013 Pages: 1485 - 1491

    

12. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases

    • Takaaki Tokito
    • Takehito Shukuya
    • Nobuyuki Yamamoto

    Original Article 27 March 2013 Pages: 1493 - 1498

    

13. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer

    • Amita Patnaik
    • Kyriakos P. Papadopoulos
    • Aby Buchbinder

    Original Article 30 March 2013 Pages: 1499 - 1506

    

14. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia

    • Siobhan Hayes
    • Paul N. Mudd Jr.
    • Ekaterina Gibiansky

    Original Article 06 April 2013 Pages: 1507 - 1520

    

15. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin^®) in cancer patients

    • Masashi Kanai
    • Yoshihiko Otsuka
    • Hiroyuki Shibata

    Original Article 30 March 2013 Pages: 1521 - 1530

    

16. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy

    • Elisabeth G. Vichaya
    • Xin Shelley Wang
    • Patrick M. Dougherty

    Original Article 31 March 2013 Pages: 1531 - 1540

    

17. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats

    • Cuirong Zhao
    • Yuanyuan Li
    • Wenbao Li

    Original Article 06 April 2013 Pages: 1541 - 1550

    

18. Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding

    • David S. Hydock
    • Chia-Ying Lien
    • Reid Hayward

    Original Article 09 April 2013 Pages: 1551 - 1560

    

19. Bevacizumab and central nervous system (CNS) hemorrhage

    • Nathalie Letarte
    • Linda R. Bressler
    • John L. Villano

    Original Article 06 April 2013 Pages: 1561 - 1565

    

20. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo

    • Aluvia M. Escalante
    • Ryan T. McGrath
    • Terry H. Landowski

    Original Article 10 April 2013 Pages: 1567 - 1576

    

21. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma

    • Ya Hua Zhong
    • Jing Dai
    • Yun Feng Zhou

    Original Article 03 April 2013 Pages: 1577 - 1583

    

22. Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil

    • Weidong Jia
    • Zhiqiang Zhu
    • Qiaohong Duan

    Original Article 16 April 2013 Pages: 1585 - 1590

    

23. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer

    • Hyeong Su Kim
    • Jung Han Kim
    • Dae Ro Choi

    Original Article 09 April 2013 Pages: 1591 - 1597

    

24. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

    • Daryl Sonnichsen
    • David J. Dorer
    • Frank G. Haluska

    Original Article Open access 23 April 2013 Pages: 1599 - 1607

    

25. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer

    • Kyu-pyo Kim
    • Ho-Sook Kim
    • Tae Won Kim

    Original Article 18 April 2013 Pages: 1609 - 1617

    

26. Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study

    • Molouk Hadjibabaie
    • Shirinsadat Badri
    • Ardeshir Ghavamzadeh

    Original Article 16 April 2013 Pages: 1619 - 1627

    

27. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer

    • Robert Amato
    • Mika Stepankiw
    • Patricia Gonzales

    Original Article 21 April 2013 Pages: 1629 - 1634

    

28. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

    • Antoinette R. Tan
    • Darlene G. Gibbon
    • Joseph J. Stephenson

    Original Article 01 May 2013 Pages: 1635 - 1643

    

29. Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

    • Noboru Yamamoto
    • Hiroshi Nokihara
    • Tomohide Tamura

    Original Article 25 April 2013 Pages: 1645 - 1655

    

30. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer

    • Taishi Hata
    • Mutsumi Fukunaga
    • Masaki Mori

    Clinical Trial Report 31 March 2013 Pages: 1657 - 1663